Crinetics Pharmaceuticals, Inc. — Director's Dealing 2019

Feb 6, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2019-02-04

Reporting Person: Versant Venture Capital V, L.P. (10% Owner)
Reporting Person: Versant Affiliates Fund V, L.P. (10% Owner)
Reporting Person: Versant Ophthalmic Affiliates I, L.P. (10% Owner)
Reporting Person: Versant Venture Capital V (Canada), LP (10% Owner)
Reporting Person: Versant Ventures V, LLC (10% Owner)
Reporting Person: Versant Ventures V (Canada), L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-02-04	Common Stock	J	445470	—	Disposed	2524456	Indirect
2019-02-04	Common Stock	J	13387	—	Disposed	75949	Indirect
2019-02-04	Common Stock	J	14828	—	Disposed	84161	Indirect
2019-02-04	Common Stock	J	33903	—	Disposed	192122	Indirect
2019-02-04	Common Stock	J	9473	—	Acquired	9473	Indirect
2019-02-04	Common Stock	J	9473	—	Disposed	0	Indirect
2019-02-04	Common Stock	J	678	—	Acquired	678	Indirect
2019-02-04	Common Stock	J	678	—	Disposed	0	Indirect

Footnotes

F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V, L.P. ("VVC V") without consideration to its partners.

F2: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VVC V; however, they each disclaim beneficial ownership of the shares held by VVC V, except to the extent of their pecuniary interests therein.

F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Affiliates Fund V, L.P. ("VAF V") without consideration to its partners.

F4: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VAF V; however, they each disclaim beneficial ownership of the shares held by VAF V, except to the extent of their pecuniary interests therein.

F5: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA") without consideration to its partners.

F6: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are managing directors of VV V and share voting and dispositive power over the shares held by VOA; however, they each disclaim beneficial ownership of the shares held by VOA, except to the extent of their pecuniary interests therein.

F7: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital V (Canada) LP ("VVC CAN") without consideration to its partners.

F8: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. By virtue of such relationships, VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. Samuel D. Colella, William J. Link, Bradley Bolzon, Ph.D., Robin L. Praeger, Kirk G. Nielson and Thomas Woiwode, Ph.D. are directors of VV V CAN GP and share voting and dispositive power over the shares held by VVC CAN; however, they each disclaim beneficial ownership of the shares held by VVC CAN, except to the extent of their pecuniary interests therein.

F9: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC V, VAF V and VOA.

F10: The shares are held VV V.

F11: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V without consideration to its members.

F12: Represents a change in the form of ownership of VV V CAN by virtue of the receipt of shares in the pro-rata in-kind distribution of Common Stock of the Issuer for no consideration by VVC CAN.

F13: The shares are held VV V CAN.

F14: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by VV V CAN without consideration to its partners.